Cancers are complex evolving systems that adapt to therapeutic intervention through a suite of resistance mechanisms, therefore whilst the maximum tolerated dose (MTD) therapies generally achieve impressive short-term responses, they unfortunately give way to treatment resistance and tumor relapse. The importance of evolution during cancer treatment is becoming more widely accepted....
Glioblastoma (GBM) is a highly invasive brain tumor, whose cells infiltrate surrounding normal brain tissue beyond the lesion outlines visible in the current medical scans. Predicting GBM infiltration is critical for designing radiotherapy treatment plans because GBM recurrence is largely driven by diffuse tumor infiltration. However, standard radiotherapy, the mainstay for treating this...
mRNA-encoded therapeutics are emerging as a promising strategy for cancer treatment, yet the quantitative link between lipid nanoparticle (LNP) delivery, intracellular mRNA processing, and systemic protein exposure remains poorly defined. We present a multiscale physiologically based pharmacokinetic (PBPK) model that integrates a parsimonious LNP–mRNA trafficking and translation layer with a...
Introduction:
Multiple myeloma (MM) is managed with complex multi-agent immunotherapy, including
daratumumab (dara), a CD38 antibody, and BCMA-targeted CAR-T cell therapy for
relapse. As the treatment landscape for MM is broad, it is important to identify
prognostic biomarkers to help personalize treatment for individuals. To investigate
immune interactions and response to immunotherapy,...
Mathematical modeling has proven to be useful for studying many biological fields and the increased focus on translational models has been a major boon to clinical research. Models benefit each stage of clinical research and have resulted in significant improvements to disease monitoring, treatment development, and the scheduling of treatment regimes \cite{scibilia2025mathematical}. Clinically...
